STOCK TITAN

Nutriband Inc - NTRB STOCK NEWS

Welcome to our dedicated page for Nutriband news (Ticker: NTRB), a resource for investors and traders seeking the latest updates and insights on Nutriband stock.

Nutriband Inc (NTRB) is a pharmaceutical innovator focused on transdermal drug delivery systems and abuse-deterrent technologies designed to enhance medication safety. This page serves as the definitive source for official company announcements, financial updates, and strategic developments.

Investors and industry stakeholders will find timely updates on AVERSA technology advancements, regulatory milestones, partnership agreements, and product pipeline progress. Our curated news collection ensures access to verified information directly impacting Nutriband’s market position and contributions to opioid safety solutions.

Key content includes earnings reports, intellectual property updates, manufacturing collaborations, and research breakthroughs. Bookmark this page to monitor Nutriband’s progress in developing transdermal therapies that address critical public health challenges while maintaining compliance with global regulatory standards.

Rhea-AI Summary

Nutriband Inc. (NASDAQ:NTRB, NTRBW) announced that the Korean Intellectual Property Office has issued a full patent for its Abuse and Misuse Deterrent Transdermal System, related to its lead technology AVERSA. This technology aims to prevent opioid abuse through taste aversion methods. A prior notice of allowance was issued in December 2020. Nutriband focuses on developing transdermal pharmaceutical products, with AVERSA designed to mitigate risks associated with abuse, misuse, and accidental exposure.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
157.8%
Tags
none
-
Rhea-AI Summary

Nutriband Inc. (NASDAQ:NTRB, NTRBW) announced a share repurchase program to buy back up to $1,000,000 of its common stock. As of December 29, 2021, the company had 7,773,962 shares outstanding. This buyback aims to enhance shareholder value and signal confidence in the company's future. Nutriband is focused on developing transdermal pharmaceutical products, particularly an abuse-deterrent fentanyl patch using its AVERSA™ technology.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9.2%
Tags
buyback
-
Rhea-AI Summary

Nutriband Inc. (NASDAQ:NTRB, NTRBW) has announced plans to offer contract manufacturing services for liquid-based topical products, following its recent cGMP certification. This certification relates to Pharmaceutical OTC GMP, 21 CFR Part 211/210, enhancing the company's manufacturing capabilities. CEO Gareth Sheridan stated that expanding these capabilities aligns with the company's revenue growth strategy for 2022. Nutriband is primarily focused on developing transdermal pharmaceutical products, including its abuse deterrent fentanyl patch utilizing AVERSA technology.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.96%
Tags
none
Rhea-AI Summary

Nutriband Inc. (NASDAQ:NTRB, NTRBW) announced that its manufacturing subsidiary, Active Intelligence, has successfully received cGMP certification after a thorough audit. This certification is vital for expanding their contract manufacturing services on a national and international scale. CEO Gareth Sheridan highlighted that this achievement will enable the company to enhance its product offerings and explore new market opportunities, which are crucial for the company’s growth strategy.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.55%
Tags
none
-
Rhea-AI Summary

Nutriband Inc. (NASDAQ:NTRB, NTRBW) announced that its CEO Gareth Sheridan and President Serguei Melnik, accompanied by board members and senior management, will ring the NASDAQ Opening Bell on December 3, 2021, at 9:30 a.m. EST. Sheridan expressed gratitude for the teamwork and support that enabled the company’s journey so far. Nutriband focuses on developing transdermal pharmaceutical products, including its lead product, an abuse deterrent fentanyl patch utilizing AVERSA™ technology. A live stream of the ceremony will be available online.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-10.43%
Tags
none
-
Rhea-AI Summary

Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW) has launched the development of its lead product, AVERSA™ Fentanyl, aiming to create the world’s first abuse-deterrent fentanyl transdermal system. This initiative follows the company's uplisting to NASDAQ and new financing. The focus will include developing a commercial strategy, market assessment, and selecting a manufacturer to expedite market entry. CEO Gareth Sheridan emphasized the importance of improving safety while ensuring accessibility for patients. Nutriband specializes in transdermal pharmaceutical products.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.11%
Tags
none
Rhea-AI Summary

Nutriband Inc. (NASDAQ:NTRB, NTRBW) announced that an interview with CEO Gareth Sheridan will air on The RedChip Money Report on Bloomberg TV on November 13 at 7 p.m. ET. The program reaches approximately 73 million homes in the U.S. RedChip has 30 years of experience in small-cap investing commentary and interviews with public company executives.

Nutriband is focused on developing transdermal pharmaceutical products, including its lead product, an abuse deterrent fentanyl patch utilizing AVERSA® technology.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.96%
Tags
none
-
Rhea-AI Summary

Nutriband Inc. (NASDAQ:NTRB, NTRBW) has announced the receipt of $2,062,500 from the exercise of 275,000 warrants at $7.50 each, linked to its earlier public offering on October 1, 2021. This adds to the $6,600,000 garnered from the sale of 1,056,000 shares, bringing the total gross proceeds to approximately $8,662,500 as of October 21, 2021. Nutriband focuses on developing transdermal pharmaceutical products, particularly an abuse deterrent fentanyl patch utilizing its AVERSA technology.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-15.81%
Tags
-
Rhea-AI Summary

Nutriband Inc. (NASDAQ:NTRB, NTRBW) has entered an exclusive manufacturing agreement with Diomics for its Diocheck™ technology, aimed at monitoring COVID-19 antibody levels. This transdermal patch provides results within 24 to 36 hours and remains effective for up to 14 days. The device is intended for assessing the effectiveness of COVID-19 vaccines over time, helping identify when boosters may be needed. The partnership showcases Nutriband's capabilities in innovative patch technologies, bolstering its position in the pharmaceutical market.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
31.08%
Tags
covid-19
Rhea-AI Summary

WallachBeth Capital has successfully completed an underwritten public offering for Nutriband Inc. (NASDAQ: NTRB), raising $6.6 million by issuing 1,056,000 units at $6.25 per unit. Each unit contains one share of common stock and one warrant, with the warrants priced at $7.50 for five years. A 45-day option to purchase additional shares and warrants has been granted to underwriters. The offering commenced trading on October 1, 2021, on the Nasdaq Capital Market.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.63%
Tags
Nutriband Inc

Nasdaq:NTRB

NTRB Rankings

NTRB Stock Data

55.86M
3.30M
70.29%
2.1%
2.53%
Biotechnology
Orthopedic, Prosthetic & Surgical Appliances & Supplies
Link
United States
ORLANDO